SLC60A1 and neoplasm: MFSD4A was identified as a new antioncogene in the present study and its expression is related to NPC prognosis, which will provide new directions for anti-tumor therapy, and could contribute to predicting prognosis by detecting immunohistochemical indicators in patients with NPC.